CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairment

CSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previously expected.

In addition to the revenue downgrade, CSL disclosed it will record a new impairment charge of about $5 billion. The write‑down reflects a reassessment of the value of certain assets.

The combined news triggered a sharp sell‑off, pushing the stock down to a nine‑year trough on the trading day. Investors appear concerned about the impact on CSL's profitability and cash flow.

Analysts note that while the impairment is sizable, it may help clean up the balance sheet and set a clearer path for future earnings, though short‑term sentiment remains negative.